Thus, in addition to treatment of micrometastatic prostate cancer, PSMA-targeting Auger-based RPT can potentially be used to treat macrometastatic disease when normal tissue toxicity must be minimized. This evidence concerns the gene FOLH1 and Familial prostate cancer.